Obesity – Page 5

Novo Nordisk and Valo Health Expand AI-Driven Collaboration to Develop Novel Treatments for Obesity, Type 2 Diabetes, and Cardiovascular Disease

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, biotech, Cardiovascular Diseases, Computational Technique, Diabetes, Drug Development, Nordisk, Obesity, Valo Health

Novo Nordisk, Valo Health, AI, Obesity, Type 2 Diabetes, Cardiovascular Disease, Drug Development, Computational Biotech

Metsera Advances with Positive Phase IIa Results for Monthly GLP-1RA Dosing

4 months ago talkbio0Tagged Clinical Trials, dosing, GLP-1RA, MET-097i, Metsera, monthly, Obesity

Metsera, GLP-1RA, MET-097i, obesity treatment, monthly dosing, weight loss, clinical trials

Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity

4 months ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Obesity, Sleep Apnea, Obstructive, tirzepatide, United States Food and Drug Administration, Zepbound

GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment

FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity

4 months ago talkbio0Tagged Approved, Obesity, Sleep Apnea, Obstructive, United States Food and Drug Administration, Zepbound

Zepbound, FDA approval, obstructive sleep apnea, obesity, tirzepatide, sleep disorder treatment

Eli Lilly’s Zepbound Wins Historic FDA Approval for Treating Obstructive Sleep Apnea in Adults with Obesity

4 months ago talkbio0Tagged Approved, Obesity, Sleep Apnea, Obstructive, United States Food and Drug Administration, Zepbound

Zepbound, tirzepatide, FDA approval, obstructive sleep apnea, obesity, weight loss, sleep disorder treatment

Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations

4 months ago talkbio0Tagged CagriSema, Expectations, investor, Nordisk, Obesity, REDEFINE 1 trial, Weight-Loss Agents

CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

4 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

4 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

4 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

4 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership